Cardio Diagnostics Holdings, Inc. (CDIO) Financial Statements
Industry: In Vitro & In Vivo Diagnostic Substances
In fiscal 2025, Cardio Diagnostics reported revenue of $14,825, down 57.5% from $34,890 the year before. Net income was -$6.5M (a -43832.5% net margin), or -$3.71 per diluted share. Operating margin was -43737.5%. Operating activities generated -$5.7M of cash, leaving -$5.9M of free cash flow. At fiscal year end, Cardio Diagnostics held $7.8M in total assets against $793,061 in total liabilities, including $0 of cash and equivalents.
Open the full interactive Cardio Diagnostics financials → Quarterly statements, key ratios, valuation history and price charts.
Cardio Diagnostics Key Stats
| Share Price | $1.75 |
|---|---|
| Market Cap | $5.2M |
| Revenue YoY Growth | -57.5% |
| 52-Week Range | $1.05 – $6.55 |
| Shares Outstanding | 3.0 million (basic, 2026 Q2) |
Cardio Diagnostics Income Statement
| FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|
| Revenue | $950 | $17,065 | $34,890 | $14,825 |
| Operating Income | -$4.5M | -$7.2M | -$8.4M | -$6.5M |
| Pre-Tax Income | -$4.7M | -$8.4M | -$8.4M | -$6.5M |
| Income Tax | $0 | — | — | — |
| Net Income | -$4.7M | -$8.4M | -$8.4M | -$6.5M |
| Diluted EPS | -$45.30 | -$19.80 | -$9.30 | -$3.71 |
Cardio Diagnostics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $2,855 | $3,555 | $2,680 | $5,360 |
| Net Income | -$1.7M | -$1.5M | -$1.8M | -$1.5M |
| Diluted EPS | -$0.98 | -$0.84 | -$0.63 | -$0.51 |
Cardio Diagnostics Balance Sheet
| FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|
| Cash & Equivalents | $0 | — | $0 | $0 |
| Current Assets | $5.9M | $2.8M | $8.8M | $5.9M |
| Total Assets | $6.2M | $4.5M | $10.6M | $7.8M |
| Current Liabilities | — | $841,142 | $631,695 | $604,839 |
| Total Liabilities | $1.9M | $1.5M | $1.1M | $793,061 |
| Shareholders' Equity | $4.3M | $3.0M | $9.6M | $7.0M |
Cardio Diagnostics Cash Flow Statement
| FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|
| Cash From Operations | -$5.1M | -$5.7M | -$5.0M | -$5.7M |
| Cash From Investing | -$368,001 | -$794,291 | -$404,190 | -$419,310 |
| Cash From Financing | $9.1M | $3.6M | $11.9M | $3.4M |
| Free Cash Flow | — | -$6.2M | -$5.2M | -$5.9M |
Figures from Cardio Diagnostics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Cardio Diagnostics financials page for every line item.
Cardio Diagnostics Company Profile
| Ticker | CDIO |
|---|---|
| Exchange | Nasdaq |
| Industry | In Vitro & In Vivo Diagnostic Substances |
| Headquarters | Chicago, Illinois |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Emerging growth company |
| SEC CIK | 0001870144 |
Frequently Asked Questions
What was Cardio Diagnostics' revenue in fiscal 2025?
Cardio Diagnostics (CDIO) reported revenue of $14,825 for fiscal 2025.
What is Cardio Diagnostics' annual revenue history?
Cardio Diagnostics' annual revenue by fiscal year: 2022: $950; 2023: $17,065; 2024: $34,890; 2025: $14,825.
What was Cardio Diagnostics' net income in fiscal 2025?
Cardio Diagnostics reported net income of -$6.5M for fiscal 2025.
What was Cardio Diagnostics' earnings per share (EPS) in fiscal 2025?
Cardio Diagnostics' diluted EPS was -$3.71 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Cardio Diagnostics generate in fiscal 2025?
Cardio Diagnostics generated -$5.9M of free cash flow in fiscal 2025.
What was Cardio Diagnostics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Cardio Diagnostics reported revenue of $5,360.
How many shares of Cardio Diagnostics are outstanding?
Cardio Diagnostics reported a weighted average of 3.0 million basic shares outstanding in 2026 Q2.
What is Cardio Diagnostics' market cap?
Based on its latest closing price, Cardio Diagnostics (CDIO) has a market capitalization of about $5.2M.
When does Cardio Diagnostics' fiscal year end?
Cardio Diagnostics' fiscal year end, as registered with the SEC, is December 31.
Where is Cardio Diagnostics headquartered?
Cardio Diagnostics lists its business address in Chicago, Illinois in its SEC filings.
Cardio Diagnostics Competitors & Similar Companies
See all 15 In Vitro & In Vivo Diagnostic Substances companies →